Advertisement
Table 3 Characteristics of patients and survival analysis (by grade of DMVD)
| Characteristic | Uniform distribution (DMVD < 10) (n = 187) | Uneven distribution (DMVD > 10) (68) | Statistics | P |
|---|---|---|---|---|
| Age (years) | 51.86 ± 9.55 | 52.04 ± 9.84 | -0.138 | 0.890 |
| Menopause | 0.389 | 0.572 | ||
| Postmenopausal | 88 | 35 | ||
| Premenopausal | 99 | 33 | ||
| Family history | 0.012 | 1.000 | ||
| No | 174 | 63 | ||
| Yes | 13 | 5 | ||
| Diameter | 2.21 ± 0.95 | 2.67 ± 1.31 | -3.061 | 0.002 |
| Quadrant | 5.680 | 0.224 | ||
| Areolar | 3 | 2 | ||
| Inner upper | 39 | 6 | ||
| Inner lower | 17 | 8 | ||
| Outer lower | 32 | 11 | ||
| Outer upper | 96 | 41 | ||
| Patterns of enhancement | 179.854 | 0.000 | ||
| Homogeneous | 77(41.2%) | 5(7.4%) | ||
| Heterogeneous | 110(58.8%) | 11(16.2%) | ||
| Peripheral | 0(0%) | 52(76.5%) | ||
| Difference of MVD (Edge - Center) | 1.29 ± 5.03 | 15.60 ± 4.27 | -20.873 | 0.000 |
| Histological grade | 2.105 | 0.349 | ||
| I | 50 | 13 | ||
| II | 120 | 46 | ||
| III | 17 | 9 | ||
| Cancer thrombosis | 1.891 | 0.204 | ||
| Negative | 140 | 45 | ||
| Positive | 47 | 23 | ||
| Nodal metastasis | 0.174 | 0.777 | ||
| Negative | 88 | 30 | ||
| Positive | 99 | 38 | ||
| Number of metastatic nodes | 2.91 ± 5.97 | 6.21 ± 9.42 | -3.302 | 0.001 |
| Clinical stage | 18.458 | 0.002 | ||
| I | 46(24.6%) | 13(19.1%) | ||
| IIA | 60(32.1%) | 16(23.5%) | ||
| IIB | 64(34.2%) | 20(29.4%) | ||
| IIIA | 11(5.9%) | 7(10.3%) | ||
| IIIB | 2(1.1%) | 5(7.4%) | ||
| IIIC | 4(2.1%) | 7(10.3%) | ||
| IV | 0(0%) | 0(0%) | ||
| ER | 18.731 | 0.000 | ||
| Negative | 57(30.5%) | 41(60.3%) | ||
| Positive | 130(69.5%) | 27(39.7%) | ||
| PgR | 26.314 | 0.000 | ||
| Negative | 48(25.7%) | 41(60.3%) | ||
| Positive | 139(74.3%) | 27(39.7%) | ||
| HER2 | 9.786 | 0.003 | ||
| Negative | 167(89.3%) | 50(73.5%) | ||
| Positive | 20(10.7%) | 18(26.5%) | ||
| Ki67 | 10.827 | 0.001 | ||
| Negative (<14%) | 120(64.2%) | 28(41.2%) | ||
| Positive (>14%) | 67(35.8%) | 40(58.8%) | ||
| P53 (%) | 32.08 ± 31.58 | 29.90 ± 33.94 | 0.479 | 0.633 |
| Clinicopathological subtypes | 42.300 | 0.000 | ||
| Luminal A | 102(54.5%) | 17(25.0%) | ||
| Luminal B (Ki67+) | 44(23.5%) | 8(11.8%) | ||
| Luminal B (HER2+) | 14(7.5%) | 8(11.8%) | ||
| HER2 overexpression | 6(3.2%) | 10(14.7%) | ||
| TNBC | 21(11.2%) | 25(36.8%) | ||
| Operation | 0.819 | 0.485 | ||
| Mastectomy | 166 | 63 | ||
| Tumorectomy | 21 | 5 | ||
| Chemotherapy program | 17.357 | 0.004 | ||
| Not performed | 0(0%) | 2(2.9%) | ||
| CMF | 2(1.1%) | 0(0%) | ||
| CAF or AC | 60(32.1%) | 12(17.6%) | ||
| CEF or EC | 43(23.0%) | 19(27.9%) | ||
| T or TC or TP | 59(31.6%) | 17(25.0%) | ||
| TAC or A-T | 23(12.3%) | 18(26.5%) | ||
| Radiotherapy | 2.012 | 0.160 | ||
| Not performed | 104 | 31 | ||
| Performed | 83 | 37 | ||
| Endocrine therapy | 38.443 | 0.000 | ||
| Not performed | 27(14.4%) | 35(51.5%) | ||
| TAM | 99(52.9%) | 20(29.4%) | ||
| LHRH | 13(7.0%) | 5(7.4%) | ||
| AI | 48(25.7%) | 8(11.8%) | ||
| Targeted therapy | 0.116 | 1.000 | ||
| Not performed | 183 | 67 | ||
| Performed | 4 | 1 | ||
| Overall survival | 99.5% | 85.3% | 24.308 | 0.000 |
| Event | 1 | 10 | ||
| Deaths | 1 | 9 | ||
| Lost to Follow-up | 0 | 1 | ||
| Median survival time | 54.0 | 54.0 | 14.885 | 0.000 |
| Disease-free survival | 99.5% | 67.6% | 62.030 | 0.000 |
| Event | 1 | 22 | ||
| Local recurrence | 0 | 1 | ||
| Contralateral breast cancer | 0 | 4 | ||
| Lung metastasis | 0 | 2 | ||
| Hepatic metastasis | 0 | 5 | ||
| Brain metastasis | 0 | 3 | ||
| Multi-organ | 1 | 6 | ||
| Lost to Follow-up | 0 | 1 | ||
| Disease-free survival | 54.0 | 31.9 | 47.546 | 0.000 |
| Follow-up time | 0.384 | 0.701 | ||
| Median | 23.0 | 22.0 | ||
| Range | 12-58 | 12-59 |
